EMAIL: SFeldman@olshanlaw.com

DIRECT DIAL: 212.451.2234

 

June 9, 2021

 

VIA EMAIL AND EDGAR

 

U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Attention: Abby Adams, Esq.,

Division of Corporation Finance,

Office of Life Sciences

 

Re:Alzamend Neuro, Inc.
Registration Statement on Form S-1 (No. 333-255955)
Registration Statement on Form 8-A (No. 001-     )     

 

Ladies and Gentlemen:

 

On behalf of Alzamend Neuro, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statements to 5:00 p.m., Eastern time, on Thursday, June 10, 2021, or as soon as possible thereafter.

 

Please advise the undersigned of the effectiveness of the Registration Statements.

 

  Very truly yours,
   
  /s/ Spencer G. Feldman
  Spencer G. Feldman

 

cc:Mr. Stephan Jackman
Henry C.W. Nisser, Esq.

 

 

 

 

 

 

ALZAMEND NEURO, INC.
3802 Spectrum Boulevard, Suite 112C
Tampa, Florida 33612

 

June 9, 2021

 

U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Attention: Abby Adams, Esq.,

Division of Corporation Finance,

Office of Life Sciences

 

Re:Alzamend Neuro, Inc.
Registration Statement on Form S-1 (No. 333-255955)
Registration Statement on Form 8-A (No. 001-      )       

 

Ladies and Gentlemen:

 

Alzamend Neuro, Inc. hereby requests that the effectiveness of the above-referenced Registration Statements be accelerated so that they will become effective at 5:00 p.m., Eastern time, on Thursday, June 10, 2021, or as soon as possible thereafter.

 

  Very truly yours,
   
  ALZAMEND NEURO, INC.
   
  By: /s/ Stephen Jackman
    Stephen Jackman
    Chief Executive Officer